Researchers found that Bristol-Myers Squibb's experimental cancer drug ipilimumab had no serious side effects in patients whose skin cancer had spread to the brain. Four of 51 patients in a midstage trial had a partial response to ipilimumab, while the drug stabilized brain and other tumors in five of 51 patients, the researchers said.

Full Story:

Related Summaries